ArticleJournal of medical virology2026
Deciphering Host Genomic Pathway Landscapes in Severe COVID-19 by Exome Sequencing of a Large Admixed Brazilian Cohort.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The host genetic factors that resulted in the heterogeneous clinical outcomes of COVID-19 remained poorly understood, especially in admixed populations that are underrepresented in global genomic studies. In this study, we investigated the genetic landscape associated with COVID-19 severity using whole-exome sequencing data from 325 Brazilian individuals recruited between 2020 and 2023. To prioritize variants related to disease severity, we applied a machine learning framework combining Support Vector Machine - Recursive Feature Elimination and SHAP interpretation. This approach encompasses 25 variants that contributed to the model's discrimination between severe and non-severe cases (AUC = 0.94) in our cohort. Subsequently, logistic regression analyses adjusted for age, sex, principal components of ancestry, and significant comorbidities confirmed several loci associated with severity after correction for multiple testing (FDR < 0.05). The prioritized genes were grouped into biological axes, including mitochondrial bioenergetics, neuroimmune signaling, complement activation, and epithelial structural integrity. Variants in genes such as MUC16, SLC4A2, LAPS1, ARRDC2, and CCSER1 showed associations with disease severity. Furthermore, functional annotation using CADD and regulatory exploration using GTEx suggested that several loci may influence gene regulation in lung, immune, and neural tissues. Instead of implicating single causal variants, our findings highlight pathway-level genetic architectures that may contribute to the variability of the host response to COVID-19. These findings provide exploratory insights into potential host genetic pathways that may be involved in disease variability in admixed environments. However, replication in independent cohorts and functional validation are still needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.